Date: 2015-06-09
Type of information: Licensing agreement
Compound: antibody-based therapies against tumor necrosis factor alpha (TNF-alpha)
Company: Tillotts Pharma (Switzerland) Numab AG (Switzerland)
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases
Type agreement: development licensing commercialisation
Action mechanism: monoclonal antibody.
Disease: inflammatory bowel disease
Details: * On June 9, 2015, Tillotts Pharma and Numab announced that they have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). Under the terms of the agreement, Tillotts will develop and commercialize new formulations of anti-TNF-α antibody fragments identified by Numab. After successful pre-clinical trials, and prior to submission of an investigational new drug (IND) application to the FDA, Tillotts will be seeking a co-development and marketing partner for the U.S. market with a strong interest in working with Tillotts to further develop antibody-based therapies that block TNF-α.
Financial terms: Numab is eligible to a signing fee and, upon successful development, will receive down- and milestone payments, as well as royalties up to double-digits.
Latest news:
